HEOR

News

NICE rejects Ipsen’s Cabometyx in thyroid cancer

Ipsen’s Cabometyx should not be used by the NHS for patients with differentiated thyroid cancer who have either not responded to or are ineligible for radioactive iodine t

News

Sought-after obesity drug Wegovy backed for NHS use

Use is restricted to two years in patients enrolled in NHS weight management services.

News

Ex-NHS chief negotiator joins Newmarket Strategy

Pharma veteran Blake Dark joins the healthcare and life sciences consultancy as senior partner.

News

More digital mental health therapies backed for NHS use

Online CBT programmes could help 40,000 people with depression and anxiety-related conditions.

News

NICE okays neoadjuvant Opdivo in lung cancer

BMS' checkpoint inhibitor is first to be given a green light for use before surgery in NSCLC.

News

As pandemic abates, NICE issues new COVID drug guidance

NICE says it is the first HTA to give guidance on the drugs outside of use during the pandemic.

NICE rejects Ipsen’s Cabometyx in thyroid cancer

Sought-after obesity drug Wegovy backed for NHS use

Ex-NHS chief negotiator joins Newmarket Strategy

More digital mental health therapies backed for NHS use

NICE okays neoadjuvant Opdivo in lung cancer

As pandemic abates, NICE issues new COVID drug guidance

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

HEOR

Editor's Picks